Teladoc Health, Inc. · NYSE:TDOC

Teladoc Health — Canaccord Genuity Annual Growth Conference 2019

23 slides from Teladoc Health's conference presentation, Aug 8, 2019

  1. Slide 1: Canaccord Genuity Annual Growth Conference

    Canaccord Genuity Annual Growth Conference August 8

  2. Slide 2: Safe harbor

    Safe harbor + This presentation contains, and our officers may make, “forward-looking” statements that are based on our management's beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limitation, information concerning poss

  3. Slide 3: Transforming how people access healthcare around the world

    At Teladoc Health, we are transforming how people access healthcare around the world. We are creating a new kind of healthcare experience – one with greater convenience, outcomes, and value.

  4. Slide 4: Teladoc Health at a glance

    TDOC +2,200 +50,000 +7,000 >9 million publicly-traded employees experts across network cumulative visits on NYSE since 2015 worldwide 450+ specialties clinicians through YE 2019

  5. Slide 5: Revenue and visit growth, key metrics

    64% 59% Revenue CAGR Visit CAGR (2016-2019E) (2016-2019E) 26.8 mm 9.7 mm US paid access US visit fee membership only lives Q2 2019 Q2 2019 68% Gross margin Q2 2019 (1) Full-year and quarter management guidance; midpoint of range, unless otherwise noted.

  6. Slide 6: Global trends are driving innovation in healthcare

    Global trends are driving innovation in healthcare Rising costs of care Aging population Physician shortages in critical specialties Consumer empowerment Limited or no access to a family doctor Data and device integrations Significant volume resulting in multi-day wait times and Offline to online tr

  7. Slide 7: Global reach and entrenched distribution

    Engagement Global Reach Science & Results Entrenched Tech-Enabled Ops at Distribution Across Category-defining brand Market leadership Consumer demand Premium pricing Scale Channels Returns to scale Proven ROI Product/Clinical Proprietary Clinical Scope of Offerings Capabilities

  8. Slide 8: Positioned to serve patients wherever they are

    Positioned to serve patients wherever they are • 40% of • 40+ US health • Public sector: • ~300 • Leading Fortune 500 plan client US federal, hospitals and behavioral including state and local health health • Thousands of municipalities commercial, systems platform small Medicare and • Medicare busi

  9. Slide 9: First and only Patient Safety Organization

    Teladoc Health Physicians Network First & only Patient Safety Organization (PSO) Staff Clinicians Telemedicine Global Expert (MDs, APs, Nurses) Practice Panel Unique clinical partnerships Quality & Strategic Oversight Teladoc Health Clinical Teladoc Health Global Medical Leadership Quality and Advis

  10. Slide 10: Distribution channels, products and growth levers

    Distribution Channels International markets Expand footprint & Hospitals & Health Systems distribution DTC Insurers Clinical services Employers innovation Products & Services Growth levers Accelerate Telemedicine New distribution consumer adoption Virtual COE specialty services Penetration of existi

  11. Slide 11: Growth levers: footprint, clinical services, consumer adoption

    Expand footprint & Clinical services Accelerate Broaden role in distribution innovation consumer adoption healthcare delivery Existing distribution Virtual Primary Care Integrated, intuitive Health System use channels consumer experiences cases Integrated Behavioral Product cross sell / Health solut

  12. Slide 12: 2017 insured population: commercial vs government lives

    2017 Insured Population - Commercial Lives vs. Government Lives (lives in millions) Military 5 Medicare FFS New Goverment 39 addressable Commercial Medicaid 177 131 72 market for 2020 Medicare Advantage 20 Note: Amounts may not sum due to rounding.

  13. Slide 13: Global opportunity

    Global opportunity Privately Insured Public Option Only 196 80 67 65 28 62 7 157 49 36 56 56 61 23 12 52 43 17 38 10 3 24 14 13 9 6 6 France Germany Netherlands UK Spain Italy Rest of Australia Canada Europe Source: NIH; OECD; CIA Factbook Note: Rest of Europe excludes Russia. Numbers may not sum du

  14. Slide 14: Delivering the Virtual First experience

    Delivering the Virtual First experience Components  Virtual front door member experience  Innovative physical & mental health services  Integrated delivery platform Benefits  Superior utilization & member satisfaction  Greater impact on healthcare costs  Deeper client partnerships

  15. Slide 15: Measures of Success

    Measures of Success Teladoc. HEALTH © 2002-2019 Teladoc Health, Inc. All rights reserved,

  16. Slide 16: Strong demand across all channels

    Strong demand across all channels Increased level of new and existing client bookings Increased RFP volume Demand for Virtual First ™ plan designs Strong interest for comprehensive, integrated solutions

  17. Slide 17: Onboarding and acquisitions driving membership

    Organic onboarding of large health plan population Acquisition of Advance Medical Acquisition of Best Doctors (1) US Paid Membership Only. (2) Pro forma to exclude Aetna Fully Insured, Amerigroup, and VFO.

  18. Slide 18: >9 million cumulative visits by YE 2019

    >9 million cumulative by YE 2019

  19. Slide 19: Utilization by cohort

    1st Year 2018 2.4x 1.6x 1.7x 1.2x 1.0x 1.0x 1.0x 1.0x 2017 Cohort 2016 Cohort 2015 Cohort 2014 Cohort (1) First year utilization measured as annualized utilization of first calendar year with eligibility. 2018 utilization reflects annualized YTD 2018 through November.

  20. Slide 20: Visits per member by product access

    40% 13% 1% (1) Products include General Medical, Expert Medical Services, Behavioral Health, and Dermatology. (2) Visits per member by product access for registered members with at least one visit YTD through November 2018.

  21. Slide 21: Teladoc Health: compelling financial model

    Teladoc Health: compelling financial model ¢ Multiple vectors driving sustainable top-line growth in a large addressable global market * High degree of visibility into future revenue streams ¢ Scalable model ¢ Approach to growth: build, buy and partner * Strong & flexible balance sheet — $480 millio

  22. Slide 22: Liquidity

    Liquidity Cash & Short Term Inv estments $472.6 Debt Cash Earliest Interest Fair Debt Conversion Rate Outstanding Expense Value Conv ertible Notes 2022 6/15/2022 3.0% $275.0 $8.3 $467.5 Conv ertible Notes 2025 11/15/2024 1.4% $287.5 $4.0 $425.3 Total 2.2% $562.5 $12.2 $892.8

  23. Slide 23: On track to achieve third quarter and full-year guidance

    On track to achieve third quarter and full-year guidance Teladoc HEALTH Revenue (M) Adjusted EBITDA (M) Visits (K) Members (M) EPS (GAAP) Q3 2019E FY 2019E $135-$138 $7-$9 800-900 28.5-29.5 $(0.40)-$(0.42) © 2002-2019 Teladoc Health, Inc. All rights reserved. $538-$545 $27-$33 3,700-4,000 29-30 $(1.

Teladoc Health — Canaccord Genuity Annual Growth Conference 2019 on 6ix